Compare Paycom Software Inc (PAYC) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Paycom Software Inc vs Tango Therapeutics Inc. — how do they compare? Paycom Software Inc trades at $238.6 (market cap $10.67B), while Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B). The key difference: Paycom Software Inc is far larger — about 2.8× Tango Therapeutics Inc.'s market cap, and Paycom Software Inc pays a 0.63% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Paycom Software Inc for 84 Days and Tango Therapeutics Inc. for 0 Days on average.
| PAYC | TNGX | |
|---|---|---|
Market Cap | $10.67B | $3.75B |
Volume | 411,289 | 9,619,106 |
Sector | Technology | Health |
52-Week High | $240.52 | $32.90 |
52-Week Low | $113.59 | $7.50 |
Typical Hold Time | 84 Days | 0 Days |
Enterprise Value | $11.45B | $2.77B |
Dividend Yield | 0.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PAYC trades at $239.00, up 1.7% today, with a bullish technical trend and strong fundamentals. The company reported Q2 2026 EPS of $2.78, beating estimates by 17%, and raised full-year guidance to 7-8% revenue growth. Valuation metrics show a P/E of 25.04 and robust profitability with a net margin of 22.78%. Recent news highlights institutional buying and positive earnings momentum.
The outlook is positive given earnings beats and raised guidance, but risks include high valuation multiples and competitive pressures. Analysts are mixed with a $211.08 consensus target, below the current price, suggesting cautious optimism. The stock's proximity to its 52-week high warrants monitoring for pullbacks.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Paycom Software Inc
Paycom is a fast-growing provider of payroll and human capital management, or HCM, software primarily targeting clients with 50-10,000 employees in the United States. Paycom was established in 1998 and services about 18,000 clients as of 2021, based on parent company grouping. Alongside its core payroll software, Paycom offers various HCM add-on modules, including time and attendance, talent management, and benefits administration.
Read more on PAYC →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
